Built for stop-loss underwriting teams

The only stop-loss intelligence that explains itself.

Competitors compress clinical nuance into a single risk score. We provide the explainability that lets underwriters price for different trajectories.

Traditional ML Risk Scores

1.47
High Risk
  • ?Why are they high risk?
  • ?What will it actually cost?
  • ?Should you laser? At what level?
  • ?What is the tail exposure?

Langentia Clinical Intelligence

Critical Risk
Every Projection Explained

58-year-old female with metastatic breast cancer, HER2+, currently on first-line HP-based therapy. Recent brain MRI suggests CNS progression. Likely transition to Enhertu (~$200K/year) with possible stereotactic radiosurgery.

Expected Cost (P50)

$395,000

Tail Exposure (P95)

$847,000

Tail driver: Enhertu-induced lung toxicity (ILD) requiring ICU, or leptomeningeal spread.

Laser Recommendation

Consider lasering at $350K specific. Therapy continuation supports corridor sizing; renewal positioning may warrant rate adjustment.

The Explainability Gap

While they're guessing, you're binding.

See why. Act now. Protect the book. Defend your price.

$350K versus $500K isn't a guess when you see the trajectory.

Multiple Myeloma: Right-Size the Laser

$180K vs $600K+ trajectory

Risk scores flag the myeloma patient. They cannot distinguish transplant-eligible ($450K first year, then maintenance) from transplant-ineligible ($200K/year ongoing). That distinction is a $250K laser decision. It's the difference between winning and overpricing the quote.

High-Risk Pregnancy: The Intervention Window

$40K term vs $1-4M+ NICU

Prior preterm birth. Short cervix. Every model flags the risk. But trajectory visibility shows the intervention window: cerclage, progesterone, MFM referral. Evidence-based interventions can reduce preterm birth risk by 25-35%, turning a $350K laser into a care coordination opportunity.

Oncology Progression: Defend Your Price

$150K vs $800K+ same diagnosis

Two members with diffuse large B-cell lymphoma (DLBCL). Same ICD code. One is first-line R-CHOP ($150K). One is third-line, CAR-T eligible ($800K+). When the broker asks “why this rate?”, you need the clinical trajectory, not just a number. Clinical reasoning is the defense.

How It Works

From census to defensible decision

Whether new business, renewal, or laser analysis - every projection traces back to clinical reasoning.

1

Upload

Secure upload of de-identified claims data. CSV or Excel formats.

30 sec

2

Analyze

AI identifies high-cost claimants, therapy trajectories, and cost drivers.

2-3 min

3

Review

Clinical narratives with expected and high-end cost projections for every flagged member.

<5 min

4

Export

Defensible documentation with laser recommendations and rate justification.

Instant

What You Get

Clinical narrativesper flagged member
Expected + high-end projectionswith cost drivers
Laser recommendationswith attachment thresholds
Defensible documentationfor broker conversations

Built for healthcare security

HIPAA Compliant
Full safeguards
SOC 2 Type II
Annual audit
No PHI Stored
Ephemeral processing

Every projection includes expected and high-end cost estimates with the clinical evidence and reasoning you need to defend it. When brokers ask “why this price?”, you have the answer.

See the difference

15-minute demo with your own sample data

We typically respond within 1 business day.

Your data is protected by HIPAA-compliant infrastructure.